MX2020000135A - Nuevos compuestos de quinolinona. - Google Patents

Nuevos compuestos de quinolinona.

Info

Publication number
MX2020000135A
MX2020000135A MX2020000135A MX2020000135A MX2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A MX 2020000135 A MX2020000135 A MX 2020000135A
Authority
MX
Mexico
Prior art keywords
compounds
quinolinone compounds
new
new quinolinone
cancer
Prior art date
Application number
MX2020000135A
Other languages
English (en)
Inventor
Qian Liu
Luoheng Qin
Haibing Guo
Zhao- Kui WAN
Wing Shun Cheung
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020000135A publication Critical patent/MX2020000135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

La invención se refiere a nuevos compuestos de quinolinona, a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para la preparación de dichos compuestos y al uso de dichos compuestos como inhibidores de FGFR (receptor del factor de crecimiento fibroblástico) y a su uso en el tratamiento de enfermedades, por ejemplo, el cáncer.
MX2020000135A 2017-06-27 2018-06-26 Nuevos compuestos de quinolinona. MX2020000135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017090267 2017-06-27
PCT/CN2018/092830 WO2019001419A1 (en) 2017-06-27 2018-06-26 NEW COMPOUNDS OF QUINOLEINONE

Publications (1)

Publication Number Publication Date
MX2020000135A true MX2020000135A (es) 2020-07-22

Family

ID=64741140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000135A MX2020000135A (es) 2017-06-27 2018-06-26 Nuevos compuestos de quinolinona.

Country Status (11)

Country Link
US (1) US11384075B2 (es)
EP (1) EP3645526A4 (es)
JP (1) JP7261752B2 (es)
KR (1) KR20200020888A (es)
CN (1) CN111032643B (es)
AU (1) AU2018291687B2 (es)
BR (1) BR112019027676A2 (es)
CA (1) CA3068081A1 (es)
MA (1) MA49522A (es)
MX (1) MX2020000135A (es)
WO (1) WO2019001419A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108433A (ko) * 2018-12-26 2021-09-02 얀센 파마슈티카 엔.브이. 티에노피리디논 화합물
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022014313A2 (pt) * 2020-01-24 2022-09-20 Syngenta Crop Protection Ag Compostos heteroaromáticos bicíclicos fundidos ativos em termos pesticidas

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
CN100526312C (zh) 2002-08-23 2009-08-12 诺华疫苗和诊断公司 苯并咪唑喹啉酮及其应用
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
KR101224410B1 (ko) * 2003-11-07 2013-01-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 퀴놀리논 화합물을 합성하는 방법
BRPI0507891A (pt) * 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
SG154451A1 (en) 2005-05-23 2009-08-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts

Also Published As

Publication number Publication date
RU2020102926A3 (es) 2021-12-21
JP2020525469A (ja) 2020-08-27
EP3645526A1 (en) 2020-05-06
RU2020102926A (ru) 2021-07-27
CN111032643B (zh) 2023-05-30
AU2018291687A1 (en) 2020-01-16
EP3645526A4 (en) 2020-10-28
US11384075B2 (en) 2022-07-12
CN111032643A (zh) 2020-04-17
MA49522A (fr) 2020-05-06
CA3068081A1 (en) 2019-01-03
WO2019001419A1 (en) 2019-01-03
KR20200020888A (ko) 2020-02-26
JP7261752B2 (ja) 2023-04-20
AU2018291687B2 (en) 2022-07-14
BR112019027676A2 (pt) 2020-09-15
US20210139470A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2018003563A (es) Nuevos compuestos.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2016014436A (es) Derivados de heterociclil-butanamida.
IN2014MU00303A (es)
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2017009608A (es) Compuestos anticancerigenos.
IN2013MU03118A (es)
MX2021007853A (es) Compuestos de tienopiridinona.
MX2021011699A (es) Derivados de quinolina y su uso para el tratamiento del cancer.
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.